{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["aging", "factors", "inflammation", "microbiome", "nutraceuticals", "phytochemicals", "polyphenols", "prostate", "supplementation", "vitamins"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36982560", "DateCompleted": {"Year": "2023", "Month": "03", "Day": "30"}, "DateRevised": {"Year": "2023", "Month": "03", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "03", "Day": "13"}], "Language": ["eng"], "ELocationID": ["5486", "10.3390/ijms24065486"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "24", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Mar", "Day": "13"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Overview of BPH: Symptom Relief with Dietary Polyphenols, Vitamins and Phytochemicals by Nutraceutical Supplements with Implications to the Prostate Microbiome.", "Abstract": {"AbstractText": ["Benign prostatic hyperplasia (BPH) is an age-related disorder, which is one of the most prevalent and costly benign neoplasms in men with over 94 million cases worldwide. Starting before or around 50 years of age, there is a linear increase in prostate volume and BPH symptoms, which are influenced by changes in hormonal, inflammatory, growth factors, cell receptor signaling, diet, physical activity, and the microbiome of the prostate that leads to cellular proliferation. While current pharmaceutical or surgical treatments are currently available, each treatment has serious side effects. This dilemma has motived men to seek treatment without negative side effects from medicinal plants such as botanicals, phytochemicals, and vitamins that have established safety records. This narrative overview focuses on several botanicals, phytochemicals and vitamins that are widely used in the treatment of BPH and emphasizes how, in some cases, combinations of these natural ingredients may provide better BPH symptom relief compared to utilization of a single medicinal plant product (monotherapy). Finally, this overview highlights in vitro, in vivo animal studies and mainly clinical data of journal reports published in the past 5 years from January 2018 to January 2023 on BPH and nutraceuticals. Notably, there is an evolving perspective or rethinking of the role that medicinal phytochemicals and natural vitamins usage play; that is, they may hold promise or are likely to alleviate BPH symptoms."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neurosensory Centers of America, Inc., Austin, TX 78738, USA."}], "LastName": "Stewart", "ForeName": "Kendal L", "Initials": "KL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cell Biology, Physiology and The Neuroscience Center, College of Life Sciences, Brigham Young University, Provo, UT 84602, USA."}], "LastName": "Lephart", "ForeName": "Edwin D", "Initials": "ED"}], "GrantList": [{"GrantID": "Life Science/TTO 19-2215", "Agency": "Brigham Young University", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Vitamins"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Prostatic Hyperplasia"}, {"QualifierName": [], "DescriptorName": "Prostate"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Vitamins"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Dietary Supplements"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Phytochemicals"}], "CoiStatement": "Edwin D. Lephart has no funding or sponsor conflicts of interest in the decision of the data/research presented in this report and regarding the publication of this manuscript. Edwin D. Lephart is an inventor on polyphenolic patents (US and worldwide) on various human health applications. Kendal Stewart has nothing to disclose."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Parsons J.K., Dahm P., K\u00f6hler T.S., Lerner L.B., Wilt T.J. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline amendment 2020. J. Urol. 2020;204:799\u2013804. doi: 10.1097/JU.0000000000001298.", "ArticleIdList": ["10.1097/JU.0000000000001298", "32698710"]}, {"Citation": "Feinstein L., Matlaga B.  Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Washington, DC, USA: 2018.  [(accessed on 16 December 2022)].  Available online:  https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/urologic-diseases-in-america."}, {"Citation": "Dirac M.A. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. GBD 2019 Benign Prostatic Hyperplasia Collaborators. Lancet. 2022;3:e754\u2013e776. doi: 10.1016/S2666-7568(22)00213-6.", "ArticleIdList": ["10.1016/S2666-7568(22)00213-6", "PMC9640930", "36273485"]}, {"Citation": "Pinto J.D.O., He H.G., Chan S.W.C., Wang W. Health-related quality of life and psychological well-being in men with benign prostatic hyperplasia: An integrative review. Jpn. J. Nurs. Sci. 2016;13:309\u2013323. doi: 10.1111/jjns.12115.", "ArticleIdList": ["10.1111/jjns.12115", "26782969"]}, {"Citation": "Peterson M.D., Belakovskiy A., McGrath R., Yarrow J.F. Testosterone deficiency, weakness, and multimorbidity. Sci. Rep. 2018;8:5897. doi: 10.1038/s41598-018-24347-6.", "ArticleIdList": ["10.1038/s41598-018-24347-6", "PMC5897450", "29651127"]}, {"Citation": "Deutschbein T., Mann K., Petersenn S. Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Infuence of Age and Body Mass Index and Establishment of Sex-Specifc Reference Ranges. Horm. Metab. Res. 2015;47:846\u2013854.", "ArticleIdList": ["25565093"]}, {"Citation": "Medline Plus, National Library of Medicine (USA)  Aging Changes in the Male Reproductive System.  [(accessed on 17 December 2022)]; Available online:  https://medlineplus.gov/ency/article/004017.htm."}, {"Citation": "Zhu A., Andino J., Daignault-Newton S., Chopra S., Sarma A., Dupree J.M. What is the normal testosterone level of young men? Rethinking the 300 ng/dL cutoff for testosterone deficiency in men 20\u201344 years old. J. Urol. 2022;6:1295\u20131302. doi: 10.1097/JU.0000000000002928.", "ArticleIdList": ["10.1097/JU.0000000000002928", "36282060"]}, {"Citation": "Lokeshwar S.D., Patel P., Fantus R.J., Halpren J., Chang C., Kargi A.Y., Ramasamy R. Decline in serum testosterone levels among adolescent and young adults in the USA. Eur. Urol. Focus. 2021;7:886\u2013889. doi: 10.1016/j.euf.2020.02.006.", "ArticleIdList": ["10.1016/j.euf.2020.02.006", "32081788"]}, {"Citation": "Madersbacher S., Sampson N., Culig Z. Patholphysiology of BPH and benign prostatic enlargement: A mini-review. Gerontology. 2019;65:458\u2013464. doi: 10.1159/000496289.", "ArticleIdList": ["10.1159/000496289", "30943489"]}, {"Citation": "Langan R.C. Benign prostatic hyperplasia. Prim. Care. 2019;46:223\u2013232. doi: 10.1016/j.pop.2019.02.003.", "ArticleIdList": ["10.1016/j.pop.2019.02.003", "31030823"]}, {"Citation": "Devlin C.M., Simms M.S., Maitland N.J. Benign prostatic hyperplasia: What do we know? BJU Int. 2021;127:389\u2013399. doi: 10.1111/bju.15229.", "ArticleIdList": ["10.1111/bju.15229", "32893964"]}, {"Citation": "Lephart E.D. Review: Anti-oxidant and anti-aging properties of equol in prostate health (BPH) Open J. Endocr. Metab. Dis. 2014;1:4\u201312. doi: 10.4236/ojemd.2014.41001.", "ArticleIdList": ["10.4236/ojemd.2014.41001"]}, {"Citation": "Lee B., Li S., Khadwala Y., Del Giudice F., Chung B.I. Efficacy and safety of 5-alpha reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS ONE. 2018;13:e0203479. doi: 10.1371/journal.pone.0203479.", "ArticleIdList": ["10.1371/journal.pone.0203479", "PMC6169865", "30281615"]}, {"Citation": "FDA Safety Announcement (USA)  5\u03b1-Reductase Inhibitors (5-ARIs) May Increase the Risk of More Serious Form of Prostate Cancer.  [(accessed on 14 January 2023)];2018  Available online:  https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-5-alpha-reductase-inhibitors-5-aris-may-increase-risk-more-serious."}, {"Citation": "Androle G., Bruckovsky N., Chung L.W.K., Matsumoto A.M., Rittimaster R., Roehrborn C., Russell D., Tindall D. Dihydrotesterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 2004;172:1399\u20131408. doi: 10.1097/01.ju.0000139539.94828.29.", "ArticleIdList": ["10.1097/01.ju.0000139539.94828.29", "15371854"]}, {"Citation": "Cai T., Cui Y., Yu S., Li Q., Zho Z., Gao Z. Comparison of Serenoa repens with Tamsulosin in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis. Am. J. Men\u2019s Health. 2020;14:1\u201311. doi: 10.1177/1557988320905407.", "ArticleIdList": ["10.1177/1557988320905407", "PMC7153190", "32274957"]}, {"Citation": "Zhu Y.-S., Imperato-McGinley J.L. 5\u03b1-Reductase isozymes and androgen actions in the prostate. Ann. N. Y. Acad. Sci. 2009;1155:43\u201356. doi: 10.1111/j.1749-6632.2009.04115.x.", "ArticleIdList": ["10.1111/j.1749-6632.2009.04115.x", "19250191"]}, {"Citation": "Flores J.M., Bernie H.L., Miranda E., Nascimento B., Schofield E., Benfanti N., Carlsson S., Mulhal J.P. The relationship between PSA and total testosterone levels in men with prostate cancer. J. Sex. Med. 2022;19:471\u2013478. doi: 10.1016/j.jsxm.2022.01.003.", "ArticleIdList": ["10.1016/j.jsxm.2022.01.003", "PMC9359436", "35135736"]}, {"Citation": "Vickman R.E., Franco O.E., Moline D.C., Vander Griend D.J., Thumbikat P., Hayward S.W. Role the androgen receptor in prostate development of benign prostatic hyperplasia. Asian J. Urol. 2020;7:191\u2013202. doi: 10.1016/j.ajur.2019.10.003.", "ArticleIdList": ["10.1016/j.ajur.2019.10.003", "PMC7385520", "32742923"]}, {"Citation": "Yu Z.-Y., Yan H.-L., Xu F.-H., Chao H.-C., Deng L.-H., Xu X.-D. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front. Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658.", "ArticleIdList": ["10.3389/fphar.2020.00658", "PMC7225336", "32457631"]}, {"Citation": "Li Z., Zhang Z., Ren Y., Wang Y., Fang J., Yue H., Ma S., Guan F. Aging and age-related diseases: From mechanisms to therapeutic strategies. Biogerontology. 2021;22:165\u2013187. doi: 10.1007/s10522-021-09910-5.", "ArticleIdList": ["10.1007/s10522-021-09910-5", "PMC7838467", "33502634"]}, {"Citation": "Franceschi C., Garagnani P., Parini P., Giulani C., Santoro A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 2018;14:576\u2013590. doi: 10.1038/s41574-018-0059-4.", "ArticleIdList": ["10.1038/s41574-018-0059-4", "30046148"]}, {"Citation": "Chung H.Y., Cesare M., Anton S., Marzetti E., Giovanni S., Seo A.Y., Carter C., Yu B.P., Leeuwenburgh C. Molecular inflammation: Underpinnings of aging and age-related disease. Ageing Res. Rev. 2009;8:18\u201330. doi: 10.1016/j.arr.2008.07.002.", "ArticleIdList": ["10.1016/j.arr.2008.07.002", "PMC3782993", "18692159"]}, {"Citation": "Xue Q., Yan Y., Zhang R., Xiong H. Regulation of iNOS on immune cells and its role in disease. Int. J. Mol. Sci. 2018;19:3805. doi: 10.3390/ijms19123805.", "ArticleIdList": ["10.3390/ijms19123805", "PMC6320759", "30501075"]}, {"Citation": "Miyake M., Tatsumi Y., Ohnishi K., Fujii T., Nakai Y., Tanaka N., Fujimoto K. Prostate disease and microbiome in the prostate, gut, and urine. Prostate Int. 2022;10:96\u2013107. doi: 10.1016/j.prnil.2022.03.004.", "ArticleIdList": ["10.1016/j.prnil.2022.03.004", "PMC9052083", "35510078"]}, {"Citation": "Yu S.H., Jung S.I. The potential role of urinary microbiome in benign prostate hyperplasia/lower urinary tract symptoms. Diagnostics. 2022;12:1862. doi: 10.3390/diagnostics12081862.", "ArticleIdList": ["10.3390/diagnostics12081862", "PMC9406308", "36010213"]}, {"Citation": "Maynard J.P., Ertunc O., Kulac I., Baena-Del Valle J.A., DeMarzo A.M., Sfanos K.S. IL-8 Expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol. Cancer Res. 2020;18:153\u2013165. doi: 10.1158/1541-7786.MCR-19-0595.", "ArticleIdList": ["10.1158/1541-7786.MCR-19-0595", "31604846"]}, {"Citation": "Santen R.J., Simpson E.R. History of estrogen: Its purification, structure, synthesis, biological actions, and clinical implications. Endocrinology. 2019;160:605\u2013625. doi: 10.1210/en.2018-00529.", "ArticleIdList": ["10.1210/en.2018-00529", "30566601"]}, {"Citation": "Blakemore J., Naftolin F. Aromatase: Contributions to physiology and disease in women and men. Physiology. 2016;31:258\u2013269. doi: 10.1152/physiol.00054.2015.", "ArticleIdList": ["10.1152/physiol.00054.2015", "27252161"]}, {"Citation": "Hemsell D.L., Grodin P.K., Siiteri P.K., McDonald P.C. Plasma precursors of estrogen II: Correlation of the extent plasma androstenedione to estrone with age. J. Clin. Endocrinol. Metab. 1974;38:476\u2013479. doi: 10.1210/jcem-38-3-476.", "ArticleIdList": ["10.1210/jcem-38-3-476", "4815174"]}, {"Citation": "Bulun S.E., Simpson E.R. Competitive RT-PCR analysis indicates levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs and abdomen of women increase with advancing age. J. Clin. Endocrinol. Metab. 1994;78:428\u2013432.", "ArticleIdList": ["8106632"]}, {"Citation": "Chen Z., Miao L., Gao X., Wang G., Xu Y. Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int. J. Clin. Exp. Med. 2015;8:11289\u201311294.", "ArticleIdList": ["PMC4565320", "26379937"]}, {"Citation": "Ellen S.J., Risbridger G.P. The dual, opposing role of estrogens in the prostate. Ann. N. Y. Acad. Sci. 2009;1155:646\u2013651. doi: 10.1111/j.1749-6632.2009.04360.x.", "ArticleIdList": ["10.1111/j.1749-6632.2009.04360.x", "19250203"]}, {"Citation": "Cannarella R., Condorelli R.A., Barbagallo R., La Vignera S., Calogero A.E. Endocrinology of the aging prostate: Current concepts. Front. Endocrinol. 2012;12:554078. doi: 10.3389/fendo.2021.554078.", "ArticleIdList": ["10.3389/fendo.2021.554078", "PMC7939072", "33692752"]}, {"Citation": "Anguiano B., de Oca C.M., Delgado-Gonzalez E., Aceves C. Prostate gland as a target of thyroid hormones: Advances and controversies. Endocr. Connect. 2022;11:e210581. doi: 10.1530/EC-21-0581.", "ArticleIdList": ["10.1530/EC-21-0581", "PMC8859956", "35041618"]}, {"Citation": "Eldhose A., Nandeesha H., Dorairajan L.N., Sreenivasulu K., Vijaya V.S. Thyroid and parathyroid hormones in benign prostatic hyperplasia. Br. J. Biomed. Sci. 2016;73:94\u201396. doi: 10.1080/09674845.2016.1173333.", "ArticleIdList": ["10.1080/09674845.2016.1173333", "27181171"]}, {"Citation": "Tran T.V., Kitahara C.M., de Vathaire F., Boutron-Ruault M.C., Journy N. Thyroid dysfunction and cancer incidence: A systematic review and meta-analysis. Endocr. Relat. Cancer. 2020;27:245\u2013259. doi: 10.1530/ERC-19-0417.", "ArticleIdList": ["10.1530/ERC-19-0417", "32045361"]}, {"Citation": "Lee J.H., Park Y.W., Lee S.W. The relationships between thyroid hormone levels and lower urinary tract symptoms/benign prostatic hyperplasia. World J. Men\u2019s Health. 2019;37:364\u2013371. doi: 10.5534/wjmh.180084.", "ArticleIdList": ["10.5534/wjmh.180084", "PMC6704305", "30644234"]}, {"Citation": "Miro C., Di Giovanni A., Murolo M., Cicatiello A.G., Nappi A., Sagliocchi S., Di Cicco E., Morra F., Celetti A., Pacifico F., et al. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022;532:215581. doi: 10.1016/j.canlet.2022.215581.", "ArticleIdList": ["10.1016/j.canlet.2022.215581", "35134514"]}, {"Citation": "Vignera S., Condorelli R.A., Cannarella R., Calogero A.E. Thyroid prostate axis. Does it really exist? World J. Men\u2019s Health. 2019;37:257\u2013260. doi: 10.5534/wjmh.190060.", "ArticleIdList": ["10.5534/wjmh.190060", "PMC6704311", "31190488"]}, {"Citation": "Man K.-M., Chen K.-B., Chen H.-Y., Chiang J.-H., Su Y.-C., Man S.S., Xie D.-D., Yang Y., Zhang A.-Q., Bi L.-K., et al. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia. Medicine. 2018;97:e12459. doi: 10.1097/MD.0000000000012459.", "ArticleIdList": ["10.1097/MD.0000000000012459", "PMC6181623", "30278528"]}, {"Citation": "Knuppel A., Fensom G.K., Watts N., Papier K., Perez-Cornago A., Schmit J.A., Byrne K.S., Travis R.C., Key T.J. Circulating IGF-1 concentrations and risk of 30 cancers: Prospective analyses in UK biobank. Cancer Res. 2020;80:4014\u20134021. doi: 10.1158/0008-5472.CAN-20-1281.", "ArticleIdList": ["10.1158/0008-5472.CAN-20-1281", "32709735"]}, {"Citation": "Mantzoros C.S., Tzonou A., Signorello L.B., Stampfer M., Trichopoilos D., Adami H.O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer. 1997;76:1115\u20131118. doi: 10.1038/bjc.1997.520.", "ArticleIdList": ["10.1038/bjc.1997.520", "PMC2228109", "9365156"]}, {"Citation": "Chokkalingam A.P., Gao Y.-T., Deng J., Stanczk F.Z., Fraumeni J.F., Jr., Hsing A.W. Insuling-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2022;52:98\u2013105. doi: 10.1002/pros.10096.", "ArticleIdList": ["10.1002/pros.10096", "12111701"]}, {"Citation": "Sreenivasulu K., Nandeessha H., Dorirajan L.N., Rajappa M., Vinayagan V., Cherupanakkai C. Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor binding protein-3 reduces with increase in prostatic size in benign prostatic hyperplasia. Aging Male. 2018;21:138\u2013144. doi: 10.1080/13685538.2017.1401994.", "ArticleIdList": ["10.1080/13685538.2017.1401994", "29129118"]}, {"Citation": "Matsushita M., Fujita K., Hatano K., De Valasco M.A., Uemura H., Nonomura N. Connecting the dots between the gut IGF-1-prostate axis: A role of IGF-1 in prostate carcinogenesis. Front. Endocrinol. 2022;13:852382. doi: 10.3389/fendo.2022.852382.", "ArticleIdList": ["10.3389/fendo.2022.852382", "PMC8965097", "35370981"]}, {"Citation": "Ali S.H., Sami A., Khudhair S.A. The role of insulin-like growth factor in developing prostate disorder in type 2 diabetic patients. Int. J. Sci. Nat. 2014;5:698\u2013702."}, {"Citation": "Celmmons D., Malie L. Interaction between insulin-like growth factor-1 receptor and alphaVbeta 3 intergrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol. Endocrinol. 2005;19:1\u201311. doi: 10.1210/me.2004-0376.", "ArticleIdList": ["10.1210/me.2004-0376", "15528274"]}, {"Citation": "Russo G.I., Castelli T., Urz\u00ec D., Privitera S., Fragal\u00e0 E., La Vignera S. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: A systematic review and meta-analysis. Aging Male. 2015;18:207\u2013216. doi: 10.3109/13685538.2015.1062980.", "ArticleIdList": ["10.3109/13685538.2015.1062980", "26171768"]}, {"Citation": "Zhou B., Wang P., Xu W.-J., Li Y.-M., Tong D.-L., Jiang J., Sun Z.-Y. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptoms score of patients with benign prostatic hyperplasia. Eur. Rev. Med. Pharmacol. Sci. 2018;22:5077\u20135081.", "ArticleIdList": ["30178825"]}, {"Citation": "Xia B.W., Zhao S.C., Chen Z.P., Chen C., Liu T.S., Yang F. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. Prostate. 2020;80:481\u2013490. doi: 10.1002/pros.23962.", "ArticleIdList": ["10.1002/pros.23962", "32104919"]}, {"Citation": "Kopp W. Diet-induced hyperinsulinemia as a key factor in the etiology of both BPH and essential hypertension? Nutr. Metab. Insights. 2018;11:1\u201311. doi: 10.1177/1178638818773072.", "ArticleIdList": ["10.1177/1178638818773072", "PMC6238249", "30455570"]}, {"Citation": "Fogaing C., Alsulihem A., Campeau L., Corcos J. Is early surgical treatment for benign prostatic hyperplasia preferable to prolonged medical therapy: Pros and cons. Medicina. 2021;57:368. doi: 10.3390/medicina57040368.", "ArticleIdList": ["10.3390/medicina57040368", "PMC8069902", "33918818"]}, {"Citation": "Chughtai B., Rojanassrot S., Nesser K., Gultyaev D., Fu S., Bhattacharyya S.K., El-Arabi A.M., Cutone B.J., McVay K.T. A comprehensive analysis of clinical quality of life, and cost-effectiveness outcomes of key treatments options of benign prostatic hyperplasia. PLoS ONE. 2022;17:e0266824. doi: 10.1371/journal.pone.0266824.", "ArticleIdList": ["10.1371/journal.pone.0266824", "PMC9012364", "35427376"]}, {"Citation": "Alegria-Torres J., Baccarelli A., Bollati V. Epigenetics and lifestyle. Epigenomics. 2011;3:267\u2013277. doi: 10.2217/epi.11.22.", "ArticleIdList": ["10.2217/epi.11.22", "PMC3752894", "22122337"]}, {"Citation": "Barnard R.J., Aaronson W.J. Benign prostatic hyperplasia: Does lifestyle play a role? Phys. Sportsmed. 2009;37:141\u2013146. doi: 10.3810/psm.2009.12.1752.", "ArticleIdList": ["10.3810/psm.2009.12.1752", "20048551"]}, {"Citation": "Erckson B.A., Vaughan-Sarrazin M., Liu X., Breyer N., Kreder K.J., Cram P. Lower urinary tract symptoms and diet quality: Findings from the 2000\u20132001 national health and nutrition examination survey. Urology. 2012;79:1262\u20131267. doi: 10.1016/j.urology.2012.03.004.", "ArticleIdList": ["10.1016/j.urology.2012.03.004", "PMC3565589", "22656406"]}, {"Citation": "La Vignera S., Basile L. Diet and prostate health: An underrated tool? Aging Male. 2022;25:60\u201364. doi: 10.1080/13685538.2022.2044468.", "ArticleIdList": ["10.1080/13685538.2022.2044468", "35212613"]}, {"Citation": "Casals R., Badalato G., Rutman M. Chapter 6: Role of diet in the development and progression of benign prostatic hyperplasia. In: Chughtai B., editor. Molecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia. Academic Press, Elsevier; London, UK: 2021. pp. 81\u201394."}, {"Citation": "Schwingshackl L., Morze J., Hoffmann G. Mediterranean diet and health status: Active ingredients and pharmacological mechanisms. Br. J. Pharmacol. 2020;177:1241\u20131257. doi: 10.1111/bph.14778.", "ArticleIdList": ["10.1111/bph.14778", "PMC7056467", "31243760"]}, {"Citation": "Wegrzyn G., Kirshenbaum E., McVay K.T. Chapter 3: Diet as a risk factor and intervention of lower urinary tract symptoms secondary to benign prostatic hyperplasia. In: Chughtai B., editor. Molecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia. Academic Press, Elsevier; London, UK: 2021. pp. 43\u201354."}, {"Citation": "Kwon J., Stoddard M.D., Chughati B. Chapter 12: Western diet and benign prostatic hyperplasia. In: Chughtai B., editor. Molecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia. Academic Press, Elsevier; London, UK: 2021. pp. 149\u2013165."}, {"Citation": "Cho A., Eidelberg A., Chughtai B. Chapter 10: Eastern diet and benign prostatic hyperplasia. In: Chughtai B., editor. Molecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia. Academic Press, Elsevier; London, UK: 2021. pp. 127\u2013136."}, {"Citation": "Johnson C.S., Shively C.A., Michalson K.T., Lea A.J., Debo R.J., Howard T.D., Hawkins G.A., Appt S.E., Liu Y., McCall C.E., et al. Contrasting effects of Western vs. Mediterranean diets in monocyte inflammatory gene expression and social behavior in a primate model. eLife. 2021;10:e68293. doi: 10.7554/eLife.68293.", "ArticleIdList": ["10.7554/eLife.68293", "PMC8423447", "34338633"]}, {"Citation": "de la Taille A., Descazeaud A., Robert G. How to prevent LUTS due to BPH development and progression. Prog. Urol. 2018;28:821\u2013829. doi: 10.1016/j.purol.2018.08.014.", "ArticleIdList": ["10.1016/j.purol.2018.08.014", "30262262"]}, {"Citation": "Das K., Buchholz N. Benign prostate hyperplasia and nutrition. Clin. Nutr. ESPEN. 2019;33:5\u201311. doi: 10.1016/j.clnesp.2019.07.015.", "ArticleIdList": ["10.1016/j.clnesp.2019.07.015", "31451276"]}, {"Citation": "ElJalby M., Thomas E., Elterman D., Chughtai B. The effect of diet on BPH, LUTS and ED. World J. Urol. 2019;37:1001\u20131005. doi: 10.1007/s00345-018-2568-0.", "ArticleIdList": ["10.1007/s00345-018-2568-0", "30470872"]}, {"Citation": "Calogero A.E., Burgio G., Condorelli R.A., Cannarella R., Ls Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22:12\u201319. doi: 10.1080/13685538.2018.1434772.", "ArticleIdList": ["10.1080/13685538.2018.1434772", "29392976"]}, {"Citation": "Russo G.I., Broggi G., Cocci A., Capogrosso P., Falcone M., Sokilakis I., Gui M., Caltabiano R., Di Mauro M. Relationship between dietary patterns with benign prostatic hyperplasia and erectile dysfunction: A collaborative review. Nutrients. 2021;13:4148. doi: 10.3390/nu13114148.", "ArticleIdList": ["10.3390/nu13114148", "PMC8618879", "34836403"]}, {"Citation": "Espinosa G., Esposito R., Kazzazi A. Vitamin D and benign prostatic hyperplasia\u2014A review. Can. J. Urol. 2013;20:6820\u20136825.", "ArticleIdList": ["23930605"]}, {"Citation": "Tan B.L., Norhaizan M.E. Oxidative stress, diet and prostate cancer. World J. Mens Health. 2021;39:195\u2013207. doi: 10.5534/wjmh.200014.", "ArticleIdList": ["10.5534/wjmh.200014", "PMC7994655", "32648373"]}, {"Citation": "Li Y., Shi B., Dong F., Zhu X., Liu B., Liu Y. Effects of inflammatory responses, apoptosis, and STAT3/NFk\u03b2- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet. Aging. 2019;11:5570\u20135582. doi: 10.18632/aging.102138.", "ArticleIdList": ["10.18632/aging.102138", "PMC6710068", "31412319"]}, {"Citation": "Murphy E.A., Velazquez K.T., Herbert K.M. Influence of high-fat diet on gut microbiome: A driving force for chronic disease risk. Curr. Opin. Clin. Nutr. Metab. Care. 2015;18:515\u2013520. doi: 10.1097/MCO.0000000000000209.", "ArticleIdList": ["10.1097/MCO.0000000000000209", "PMC4578152", "26154278"]}, {"Citation": "Wang X., Wang Y., Gratzke C., Sterr C., Yu Q., Li B., Strittmatter F., Herlemann A., Tamalunas A., Rutz B., et al. Ghrelin aggravates prostate enlargement in rats with testosterone-induced benign prostatic hyperplasia, stromal cell proliferation, and smooth muscle contraction in human prostate tissue. Oxidative Med. Cell. Longev. 2019;1:1\u201314. doi: 10.1155/2019/4748312.", "ArticleIdList": ["10.1155/2019/4748312", "PMC6893282", "31885795"]}, {"Citation": "Gu M., Liu C., Yang T.-Y., Zhan M., Cai A., Chen Y., Chen Q., Wang Z. High-fat diet induced gut microbiota alterations associating with ghrelin/JAK2/Stat3 up-regulation to promote benign prostatic hyperplasia development. Front. Cell Dev. Biol. 2021;9:615928. doi: 10.3389/fcell.2021.615928.", "ArticleIdList": ["10.3389/fcell.2021.615928", "PMC8264431", "34249898"]}, {"Citation": "Eleazu C., Eleazu K., Kalu W. Management of benign prostatic hyperplasia: Could dietary polyphenols be an alternative to existing therapies? Front. Pharmacol. 2017;8:234. doi: 10.3389/fphar.2017.00234.", "ArticleIdList": ["10.3389/fphar.2017.00234", "PMC5408066", "28503148"]}, {"Citation": "Hu X., Li X., Deng P., Zhang Y., Liu R., Cai D., Zu Q., Jiang X., Sun J., Bai W. The consequence and mechanism of dietary flavonoids on androgen profiles and disorders of amelioration. Crit. Rev. Food Sci. Nutr. 2022;7:1\u201324. doi: 10.1080/10408398.2022.2090893.", "ArticleIdList": ["10.1080/10408398.2022.2090893", "35796699"]}, {"Citation": "Jantan I., Haque A., Arshad L., Harikrishnan H., Septama A.W., Mohmed-Hussein A.-Z. Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. J. Nutr. Biochem. 2021;93:108634. doi: 10.1016/j.jnutbio.2021.108634.", "ArticleIdList": ["10.1016/j.jnutbio.2021.108634", "33794330"]}, {"Citation": "Rakha A., Umar N., Rabail R., Butt M.S., Kieliszek M., Hassoun A., Aadil R.M. Anti-inflammatory and anti-allergic potential of dietary flavonoids: A review. Biomed. Pharmacother. 2022;156:113945. doi: 10.1016/j.biopha.2022.113945.", "ArticleIdList": ["10.1016/j.biopha.2022.113945", "36411631"]}, {"Citation": "Trinchieri A. Soy in benign prostate hyperplasia and prostate cancer: A literature review. Longua Clin. Med. 2022;5:9. doi: 10.21037/lcm-21-36.", "ArticleIdList": ["10.21037/lcm-21-36"]}, {"Citation": "Berg G., Rybakova D., Fischer D., Cernava T., Verg\u00e8s M.-C.C., Charles T., Chen X., Cocolin L., Eversole K., Corral G.H., et al. Microbiome definition re-visited: Old concepts and new challenges. Microbiome. 2020;8:103. doi: 10.1186/s40168-020-00875-0.", "ArticleIdList": ["10.1186/s40168-020-00875-0", "PMC7329523", "32605663"]}, {"Citation": "Gilbert J., Blaser M.J., Caporaso J.G., Jansson J.K., Lynch S.V., Knight R. Current understanding of the human microbiome. Nat. Med. 2018;24:392\u2013400. doi: 10.1038/nm.4517.", "ArticleIdList": ["10.1038/nm.4517", "PMC7043356", "29634682"]}, {"Citation": "Kho Z.Y., Lal S.K. The human gut microbiome a potential controller of wellness and disease. Front. Microbiol. 2018;9:1835. doi: 10.3389/fmicb.2018.01835.", "ArticleIdList": ["10.3389/fmicb.2018.01835", "PMC6102370", "30154767"]}, {"Citation": "Lephart E.D., Naftolin F. Estrogen action and gut metabolism in dermal health. Dermatol. Ther. 2022;12:1535\u20131550. doi: 10.1007/s13555-022-00759-1.", "ArticleIdList": ["10.1007/s13555-022-00759-1", "PMC9276867", "35752663"]}, {"Citation": "Kim M.S., Jung S.I. The urinary tract microbiome in male genitourinary diseases: Focusing on benign prostate hyperplasia and lower urinary tract symptoms. Int. Neurourol. 2021;25:3\u201311. doi: 10.5213/inj.2040174.087.", "ArticleIdList": ["10.5213/inj.2040174.087", "PMC8022174", "33504133"]}, {"Citation": "Fr\u01fflund A., Wikstrom A., Lidbrink P., Abu A.-S.W., Larsen N., Harder C.B. The bacterial microbiota in first-void urine from men with and without idiophatic urethritis. PLoS ONE. 2018;13:e0201380. doi: 10.1371/journal.pone.0201380.", "ArticleIdList": ["10.1371/journal.pone.0201380", "PMC6063444", "30052651"]}, {"Citation": "Holland B., Karr M., Delfino K., Dynda D., El-Zawahry A., Braundmeier-Fleming A., McVary K., Alanee S. The effect of the urinary and faecal microbiota on lower urinary tract symptoms measured by the international prostate symptom score: Analysis utilising next-generation sequencing. BJU Int. 2020;125:905\u2013910.", "ArticleIdList": ["31837098"]}, {"Citation": "Liu X., Mao B., Gu J., Wu J., Cui S., Wang G., Zhao J., Zhang H., Chen W. Blautia\u2014A new functional genus with potential probiotic properties? Gut Microbes. 2021;13:e1875796. doi: 10.1080/19490976.2021.1875796.", "ArticleIdList": ["10.1080/19490976.2021.1875796", "PMC7872077", "33525961"]}, {"Citation": "Bajic P., Van Kuiken M.E., Burge B.K., Kirshenbaum E.J., Joyce C.J., Wolfe A.J. Male bladder microbiome relates to lower urinary tract symptoms. Eur. Urol. Focus. 2020;6:376\u2013382. doi: 10.1016/j.euf.2018.08.001.", "ArticleIdList": ["10.1016/j.euf.2018.08.001", "30143471"]}, {"Citation": "Jain S., Samal A.G., Das B., Pradhan B., Sahu N., Mohapatra D., Behera P.K., Mohanty A.K. Escherischia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells. Prostate. 2020;80:1341\u20131352. doi: 10.1002/pros.24063.", "ArticleIdList": ["10.1002/pros.24063", "32835423"]}, {"Citation": "Lee H.-Y., Wang J., Juan Y.-S., Li C.C., Liu C.-J., Cho S.Y., Yeh H.-C., Chueh A.-S., Wu W.-J., Wu D. The impact of urine microbiota in patients with lower tract symptoms. Ann. Clin. Microbiol. Antimicrob. 2021;29:1\u201312. doi: 10.1186/s12941-021-00428-9.", "ArticleIdList": ["10.1186/s12941-021-00428-9", "PMC8051042", "33858430"]}, {"Citation": "Yin S., Xu D., Zhang M., Zhang P., Guan Y., Kzhyshkowska J., Liang C. Urine flora imbalance and new biomarkers in prostate cancer and benign prostatic hyperplasia. Arch. Med. Sci. 2021;4:1\u201311. doi: 10.5114/aoms/135380.", "ArticleIdList": ["10.5114/aoms/135380"]}, {"Citation": "Fujita K., Matsushita M., Banno E., De Velasco M.A., Hatano K., Nonomura N., Uemura H. Gut microbiome and prostate cancer. Int. J. Urol. 2022;29:793\u2013798. doi: 10.1111/iju.14894.", "ArticleIdList": ["10.1111/iju.14894", "35388531"]}, {"Citation": "Piwowarski J.P., Stanislawska I., Granica S. Dietary polyphenols and microbiota interactions in the context of prostate health. Ann. N. Y. Acad. Sci. 2022;1508:54\u201377. doi: 10.1111/nyas.14701.", "ArticleIdList": ["10.1111/nyas.14701", "34636052"]}, {"Citation": "Kumar N.B., Hogue S., Pow-Sang J., Poch M., Manley B.J., Li R., Dhillon J., Yu A., Byrd D.A. Effects of green tea catchins on prostate cancer chemoprevention: The role of the gut microbiome. Cancers. 2022;14:3988. doi: 10.3390/cancers14163988.", "ArticleIdList": ["10.3390/cancers14163988", "PMC9406482", "36010981"]}, {"Citation": "Mishra S., Stierman B., Gahche J.J., Potischman N. NCHS Data Brief. Centers for Disease Control and Prevention; Atlanta, GA, USA: 2021. Dietary Supplement Use Among Adults: United States, 2017\u20132018; pp. 1\u20138.", "ArticleIdList": ["33663653"]}, {"Citation": "Feng Z., Yang J., Xu M., Lin R., Yang H., Lai L., Wang Y., Wahner-Roedler D.L., Zhou X., Shin K.M. Dietary supplements and herbal medicine for COVID-19: A systematic review of randomized control trials. Clin. Nutr. ESPEN. 2021;44:50\u201360. doi: 10.1016/j.clnesp.2021.05.018.", "ArticleIdList": ["10.1016/j.clnesp.2021.05.018", "PMC8166807", "34330513"]}, {"Citation": "Zhang Z., Zhang X., Bi K., He Y., Yan W., Yang C.S., Zhang J. Potential protective mechanism of green tea polyphenol EGCG against COVID-19. Trends Food Sci. Tech. 2021;114:11\u201324. doi: 10.1016/j.tifs.2021.05.023.", "ArticleIdList": ["10.1016/j.tifs.2021.05.023", "PMC8146271", "34054222"]}, {"Citation": "Council for Responsible Nutrition  2020 CRN Consumer Survey on Dietary Supplements.  [(accessed on 29 December 2022)].  Available online:  https://www.crnusa.org/resources/2020-crn-consumer-survey-dietary-supplements."}, {"Citation": "Buckingham J. Dictionary of Natural Products on DVD. CRC Press; Boca Raton, FL, USA: 2014."}, {"Citation": "Lui R.H. Health-promoting components of fruits and vegetables in the diet. Adv. Nutr. 2013;4:384S\u2013392S.", "ArticleIdList": ["PMC3650511", "23674808"]}, {"Citation": "Csikos E., Horvath A., Acs K., Papp N., Balazs V.L., Dolenc S., Kenda M., Glavac N.K., Nagy M., Protti M., et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules. 2021;26:7141. doi: 10.3390/molecules26237141.", "ArticleIdList": ["10.3390/molecules26237141", "PMC8659259", "34885733"]}, {"Citation": "Nutrition Guide for Clinicians  Benign Prostatic Hyperplasia. 2022.  [(accessed on 29 December 2022)].  Pages 1 to 6. Available online:  https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition_Guide_for_Clinicians/1342049/allBenign_Prostatic_Hyperplasia."}, {"Citation": "Mitsunari K., Miyata Y., Matsuo T., Mukae Y., Otsubo A., Harada J., Kondo T., Matsuda T., Ohba K., Sakai H. Pharmacological effects and potential clinical usefulness of polyphenols in benign prostatic hyperplasia. Molecules. 2021;26:450. doi: 10.3390/molecules26020450.", "ArticleIdList": ["10.3390/molecules26020450", "PMC7829696", "33467066"]}, {"Citation": "Chung A., Kini M., Hartigan S.M., Chughtai B., Dmochowski R.R. Chapter 8: Nutritional supplementation for benign prostatic hyperplasia. In: Chughtai B., editor. Molecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia. Academic Press, Elsevier; London, UK: 2021. pp. 107\u2013111."}, {"Citation": "Lephart E.D. Skin aging and oxidative stress: Equol\u2019s anti-aging effects via biochemical and molecular mechanisms. Ageing Res. Rev. 2016;31:36\u201354. doi: 10.1016/j.arr.2016.08.001.", "ArticleIdList": ["10.1016/j.arr.2016.08.001", "27521253"]}, {"Citation": "Sajid M., Stone R., Kaur P. Recent advances in heterologous synthesis paving way for future green modular bioindustries: A review with special reference to isoflavonoids. Front. Bioeng. Biotech. 2021;9:673270. doi: 10.3389/fbioe.2021.673270.", "ArticleIdList": ["10.3389/fbioe.2021.673270", "PMC8282456", "34277582"]}, {"Citation": "Setchell K.D., Clerici C. Equol: Pharmacokinetics and biological actions. J. Nutr. 2010;140:1363S\u20131368S. doi: 10.3945/jn.109.119784.", "ArticleIdList": ["10.3945/jn.109.119784", "PMC2884334", "20519411"]}, {"Citation": "Fatima A., Khan M.A., Ahmad M.W. Therapeutic potential of equol: A comprehensive review. Curr. Pharm. Des. 2020;26:5837\u20135843. doi: 10.2174/1381612826999201117122915.", "ArticleIdList": ["10.2174/1381612826999201117122915", "33208061"]}, {"Citation": "Pejcic T., Tosti T., Dzamic Z., Gasic U., Vuksanovic A., Dolicanin Z., Tesic Z. The polyphenols as potential agents in prevention and therapy of prostate diseases. Molecules. 2019;24:3982. doi: 10.3390/molecules24213982.", "ArticleIdList": ["10.3390/molecules24213982", "PMC6864651", "31689909"]}, {"Citation": "Piroten A., Bravo D., Jandete J.M. Bacterial metabolism as responsible of beneficial effects of phytoestrogens on human health. Crit. Rev. Food Sci. Nutr. 2019;60:1922\u20131937. doi: 10.1080/10408398.2019.1622505.", "ArticleIdList": ["10.1080/10408398.2019.1622505", "31161778"]}, {"Citation": "Hwang N.M., Stabile L.P. Estrogen receptor \u03b2 in cancer: To \u03b2(e) or not to \u03b2(e)? Endocrinology. 2021;162:11\u201315. doi: 10.1210/endocr/bqab162.", "ArticleIdList": ["10.1210/endocr/bqab162", "34370841"]}, {"Citation": "Akca K.T., Demirel M.A., Ipek S. The role of aromatase enzyme in hormone related diseases and plant-based aromatase inhibitors as therapeutic regimens. Curr. Top. Med. Chem. 2021;22:229\u2013246. doi: 10.2174/1568026621666211129141631.", "ArticleIdList": ["10.2174/1568026621666211129141631", "34844542"]}, {"Citation": "Lephart E.D. Modulation of aromatase by phytoestrogens. Enzym. Res. 2015:594656. doi: 10.1155/2015/594656.", "ArticleIdList": ["10.1155/2015/594656", "PMC4699002", "26798508"]}, {"Citation": "Lephart E.D. Phytoestrogens (resveratrol and equol) for estrogen-deficient skin-controversies/misinformation versus anti-aging in vitro and clinical evidence via nutraceutical-cosmetics. Int. J. Mol. Sci. 2021;22:11218. doi: 10.3390/ijms222011218.", "ArticleIdList": ["10.3390/ijms222011218", "PMC8538984", "34681876"]}, {"Citation": "Reed K.E., Camargo J., Hamilton-Reeves J., Kurzer M., Messina M. Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies. Reprod. Tox. 2021;100:60\u201367. doi: 10.1016/j.reprotox.2020.12.019.", "ArticleIdList": ["10.1016/j.reprotox.2020.12.019", "33383165"]}, {"Citation": "Lephart E.D. Severe & moderate BPH symptoms in mid-aged men improve with isoflavonoid-equol treatment: Pilot intervention study. Open J. Urol. 2013;3:21\u201327."}, {"Citation": "Cicero A.F.G., Allkanjari O., Busetto G.M., Cai T., Largana G., Magri V., Perletti G., Della Cuna F.S.R., Russo G.I., Stamatiou K., et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch. Ital. Di Urol. E Androl. 2019;91:3. doi: 10.4081/aiua.2019.3.139.", "ArticleIdList": ["10.4081/aiua.2019.3.139", "31577095"]}, {"Citation": "Hirvonen J., Ragalin A.M., Wohlfahrt G., Adlercreutz H., Wahhala K., Aarnisalo P. Transcriptional activity of estrogen-related receptor gamma (ERR-\u03b3) is stimulated by the phytoestrogen equol. J. Steroid Biochem. Mol. Biol. 2011;123:46\u201357. doi: 10.1016/j.jsbmb.2010.11.001.", "ArticleIdList": ["10.1016/j.jsbmb.2010.11.001", "21056663"]}, {"Citation": "Jackson R. Safety and Pharmacokinetics Study of S-Equol in Healthy Volunteers.  [(accessed on 23 December 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00787007."}, {"Citation": "Takeda T., Shiina M., Chiba Y. Effectiveness of natural S-equol supplements for premenstrual symptoms: Randomized double-blind, placebo-controlled trial. BMJ Open. 2018;8:e023314. doi: 10.1136/bmjopen-2018-023314.", "ArticleIdList": ["10.1136/bmjopen-2018-023314", "PMC6059334", "30021756"]}, {"Citation": "Yoshikata R., Myint K.Z.M., Ohta H., Ishigaki Y. Effects of equol-containing supplement on advanced glycation end products, visceral fat and climacteric symptoms in postmenopausal women: A randomized controlled trial. PLoS ONE. 2021;16:e0257332. doi: 10.1371/journal.pone.0257332.", "ArticleIdList": ["10.1371/journal.pone.0257332", "PMC8432832", "34506596"]}, {"Citation": "Tuli H.S., Kumar A., Sak K., Aaggarwal D., Gupta D.S., Kaur G., Vashishth K., Dhama K., Karur J., Saini A.K., et al. Gut microbiota-assisted synthesis, cellular interactions and synergistic perspectives of equol as a potent anticancer isoflavone. Pharmaceuticals. 2022;15:1418. doi: 10.3390/ph15111418.", "ArticleIdList": ["10.3390/ph15111418", "PMC9697248", "36422548"]}, {"Citation": "Gupta E. \u03b2-Sitosterol: Predominant phytosterol of therapeutic potential. In: Mishra P., editor. Innovations in Food Technology. Springer Nature; Berlin, Germany: 2020. pp. 465\u2013477."}, {"Citation": "Chanioti S., Katsouli M., Tzia C. A Centum of Valuable Plant Bioactives. Elsevier; London, UK: 2021. Chapter 9\u2014\u03b2-Sitosterol as a functional bioactive; pp. 193\u2013217."}, {"Citation": "Yadav P., Chauhan C., Singh S., Banerjee S., Krishna M. \u03b2-Sitosterol in various pathological conditions: An update. Curr. Bioact. Compd. 2022;18:19\u201327."}, {"Citation": "Khan Z., Nath N., Rauf A., Emran T.B., Mitra S., Islam F., Chandran D., Barua J., Khandaker U., Idris A.M., et al. Multifunctional roles and pharmacological potent of \u03b2-sitosterol: Emerging evidence toward clinical applications. Chem.-Biol. Interact. 2022;365:110117. doi: 10.1016/j.cbi.2022.110117.", "ArticleIdList": ["10.1016/j.cbi.2022.110117", "35995256"]}, {"Citation": "Babu S., Jayaraman S. An update on \u03b2-sitosterol: A potential herbal nutraceutical for diabetic management. Biomed. Pharmcother. 2020;131:110702. doi: 10.1016/j.biopha.2020.110702.", "ArticleIdList": ["10.1016/j.biopha.2020.110702", "32882583"]}, {"Citation": "Klippel K.F., Hiltl D.M., Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto study group. Br. J. Urol. 1997;80:427\u2013432. doi: 10.1046/j.1464-410X.1997.t01-1-00362.x.", "ArticleIdList": ["10.1046/j.1464-410X.1997.t01-1-00362.x", "9313662"]}, {"Citation": "Cosentino V., Militello A., Lauria G. Short-term effects of dietary supplement on lower urinary tract symptoms. J. Biol. Regul. Homeost. Agents. 2018;32:1557\u20131563.", "ArticleIdList": ["30518201"]}, {"Citation": "Sudeep H.V., Venkatakrishna K., Amrutharaj B., Shyamprasad A.-K. A phytosterol-enriched saw palmetto supercritical CO2 extract ameliorates testosterone-induced benign prostatic hyperplasia by regulation the inflammatory and apoptotic proteins in a rat model. BMC Complement. Altern. Med. 2019;19:270. doi: 10.1186/s12906-019-2697-z.", "ArticleIdList": ["10.1186/s12906-019-2697-z", "PMC6798398", "31623582"]}, {"Citation": "Sudeep H.V., Thomas J.V., Shyamprasad K. A double-blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urol. 2020;20:86. doi: 10.1186/s12894-020-00648-9.", "ArticleIdList": ["10.1186/s12894-020-00648-9", "PMC7333342", "32620155"]}, {"Citation": "Bao X., Zhang Y., Zhang H., Xia L. Molecular mechanisms of \u03b2-sitosterol and its derivatives in tumor progression. Front. Oncol. 2022;12:926975. doi: 10.3389/fonc.2022.926975.", "ArticleIdList": ["10.3389/fonc.2022.926975", "PMC9213880", "35756648"]}, {"Citation": "Devi N.M., Prasad R.V., Sagaroka N. A review of the health benefits and nutritional composition of pumpkin seeds. Int. J. Chem. Stud. 2018;6:1154\u20131157."}, {"Citation": "Devi N.M., Prasad R.V., Palmei G. Physico-chemical characteristics of pumpkin seeds. Int. J. Chem. Stud. 2018;6:828\u2013831."}, {"Citation": "Ramak P., Mahboubi M. The beneficial effects of pumpkin (Cucurbita pepo L.) seed oil for health condition of men. Food Rev. Int. 2019;2:166\u2013176. doi: 10.1080/87559129.2018.1482496.", "ArticleIdList": ["10.1080/87559129.2018.1482496"]}, {"Citation": "Nattagh-Eshtivani E., Barghachi H., Pahlavani N., Barati M., Amri Y., Fadel A., Khosravi M., Talebi S., Arzhang P., Ziaei R., et al. Biological and pharmacological effects and nutritional impacts of phytosterols. Phytother. Res. 2022;36:299\u2013322. doi: 10.1002/ptr.7312.", "ArticleIdList": ["10.1002/ptr.7312", "34729825"]}, {"Citation": "Kang X.-C., Chen T., Zhou J.-I., Shen P.-Y., Dai S.-H., Gao G.-Q., Zhang J.-Y., Xiong X.-Y., Liu D.-B. Phytoesterols in hull-less pumpkin seed oil, rich in delta-7-phyosterols, ameliorate benign prostatic hyperplasia by lowering 5\u03b1-reductase and regulating balance between cell proliferation and apoptosis in rats. Food Nutr. Res. 2021;65:7537. doi: 10.29219/fnr.v65.7537.", "ArticleIdList": ["10.29219/fnr.v65.7537", "PMC8693601", "34984064"]}, {"Citation": "Vollmer D.L., West V.A., Lephart E.D. Enhancing skin health: By oral administration of natural compounds and minerals with implications to the dermal microbiome. Int. J. Mol. Sci. 2018;19:3059. doi: 10.3390/ijms19103059.", "ArticleIdList": ["10.3390/ijms19103059", "PMC6213755", "30301271"]}, {"Citation": "Leibbrand M., Siefer S., Schon C., Perrijaquet-Moccett T., Kompek A., Csernich A., Bucar F., Kreuter M.H. Effects of an oil-free hydroethanolic pumpkin seed extract on symptom frequency and severity in men with benign prostatic hyperplasia: A pilot study in humans. J. Med. Food. 2019;22:551\u2013559. doi: 10.1089/jmf.2018.0106.", "ArticleIdList": ["10.1089/jmf.2018.0106", "PMC6590724", "31017505"]}, {"Citation": "Zerafatjou N., Amirzargar M., Biglarkhani M., Shobeirian F., Zoghi G. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: A single-blind randomized clinical trial. BMC Urol. 2021;21:147. doi: 10.1186/s12894-021-00910-8.", "ArticleIdList": ["10.1186/s12894-021-00910-8", "PMC8527717", "34666728"]}, {"Citation": "Theil G., Richter M., Schulze M., Kottig T., Patz B., Heim S., Kraub Y., Markov M., Fornara P. Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: A 24-month noninterventional study. World J. Urol. 2022;40:1769\u20131775. doi: 10.1007/s00345-022-04036-w.", "ArticleIdList": ["10.1007/s00345-022-04036-w", "PMC9236993", "35622117"]}, {"Citation": "Vahlensieck W., Heim S., Patz B., Sahin K. Beneficial effects of pumpkin seed soft extract on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia: A meta-analysis of two randomized, placebo-controlled trials over 12 months. Clin. Phytoscience. 2022;8:13. doi: 10.1186/s40816-022-00345-0.", "ArticleIdList": ["10.1186/s40816-022-00345-0"]}, {"Citation": "Bach D. Placebokontrollierte Langzeittherapiestudie mit K\u00fcrbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Der Urol. B. 2000;40:437\u2013443. doi: 10.1007/s001310050432.", "ArticleIdList": ["10.1007/s001310050432"]}, {"Citation": "Vahlensieck W., Theurer C., Pftzer E., Patz B., Banik N., Engelmann U. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, Placebo-Controlled GRANU Study. Urol. Int. 2015;94:286\u2013295. doi: 10.1159/000362903.", "ArticleIdList": ["10.1159/000362903", "25196580"]}, {"Citation": "Nemr E., Helou E.E., Mjaess G., Semaan A., Chebel J.A. Prospective mutlicenter open-label one-arm trial investigating a pumpkin seed, isoflavonoids, and cranberry mix in lower urinary tract symptoms/benign prostatic hyperplasia: A pilot study. Adv. Urol. 2020:63254900. doi: 10.1155/2020/6325490.", "ArticleIdList": ["10.1155/2020/6325490", "PMC7083134", "32215007"]}, {"Citation": "Foster S. The historical interplay of plant biology, trade, and human interactions with Saw Palmetto. HerbalGram. 2021;132:36\u201376."}, {"Citation": "Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci. Biotechnol. 2019;28:1599\u20131606. doi: 10.1007/s10068-019-00605-9.", "ArticleIdList": ["10.1007/s10068-019-00605-9", "PMC6859144", "31807332"]}, {"Citation": "Vela-Navarrete R., Alcaraz A., Rodriguez-Antolin A., Lopez B.M., Fernandez-Gomez J.M., Angulo J.C., Diaz D.C., Romero-Otero J., Brenes F.J., Carballido J., et al. Efficacy and safety of a hexanic extract of Serenoa repens (Perixon\u00ae) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): Systematic review and meta-analysis of randomized controlled trials and observational studies. BJU Int. 2018;122:1049\u20131065.", "ArticleIdList": ["29694707"]}, {"Citation": "De Monte C., Carradori S., Granese A., Di Pierro G.B., Leonardo C., De Numzio C. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms.  [(accessed on 29 December 2022)];BMC Urol. 2014 14:63.  doi: 10.1186/1471-2490-14-63. Available online:  http://www.biomedcentral.com/1471-2490/14/63.", "ArticleIdList": ["10.1186/1471-2490-14-63", "PMC4136420", "25112532"]}, {"Citation": "Blair H.A. Hexanic extract of Serenoa repens (Perixon\u00ae): A review in symptomatic benign prostatic hyperplasia. Drugs Aging. 2022;39:235\u2013243.", "ArticleIdList": ["PMC9192452", "35237936"]}, {"Citation": "Penugonda K., Lindshield B.L. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients. 2013;5:3617\u20133633. doi: 10.3390/nu5093617.", "ArticleIdList": ["10.3390/nu5093617", "PMC3798925", "24067389"]}, {"Citation": "European Medicines Agency  Assessment Report on Serenoa repens (W. Bartram) Small, Fructus. Final. 2015.  [(accessed on 16 December 2022)].  Available online:  https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-report/final-assessment-report-serenoa-repens-w-bartram-small-fructus_en.pdf."}, {"Citation": "European Medicines Agency  European Union Herbal Monograph on Serenoa repens (W. Bartram) Small, Fructus. 2014.  [(accessed on 17 December 2022)].  Available online:  https://www.ema.europa/eu/en/documents/herbal-monograph/draft/european-union-herbal-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf."}, {"Citation": "Karanasagara S., Hong G.-L., Jung D.-Y., Kim K.-H., Cho K., Jung J.-Y. Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5\u03b1-reductase type 2 and induced apoptosis. PLoS ONE. 2020;15:e0236879. doi: 10.1371/journal.pone.0236879.", "ArticleIdList": ["10.1371/journal.pone.0236879", "PMC7425886", "32790676"]}, {"Citation": "De Nunzio C., Salonia A., Gacci M., Ficarra V. The role of combination therapy with \u03b1-blockers and hexanic extract of Serenoa repens in the treatment of LUTS/BPH. J. Clin. Med. 2022;11:7169. doi: 10.3390/jcm11237169.", "ArticleIdList": ["10.3390/jcm11237169", "PMC9736252", "36498751"]}, {"Citation": "Nickel J.C., Chughai B., De Nunizo C., Brahmbhatt J., Shore N., Te A.E., Djavan B. Rethinking the role of Saw Palmetto extract for men with lower urinary tract symptoms in North America. Urology. 2022;1:137\u2013150. doi: 10.3390/uro2030017.", "ArticleIdList": ["10.3390/uro2030017"]}, {"Citation": "Khan U.H., Sevindik M., Zarrabi M., Nami M., Ozdemir B., Kaplan D.N., Selamoglu Z., Hasan M., Kumar M., Alsheri M.M., et al. Food sources, biological activities, and human health benefits. Oxidative Med. Cell Longev. 2021:2713522. doi: 10.1155/2021/2713511.", "ArticleIdList": ["10.1155/2021/2713511", "PMC8626194", "34840666"]}, {"Citation": "Srivastave S. Lycopene: Metabolism and functional aspects. In: Merillon J.M., Ramawat K., editors. Bioactive Molecules in Food. Springer Nature; Cham, Switzerland: 2019. pp. 903\u2013918.", "ArticleIdList": ["10.1007/978-3-319-78030-6_92"]}, {"Citation": "Imran M., Ghorat F., Ul-Haq I., Ur-Rehman H., Aslam F., Heydari M., Shariatti M.A., Okushanova E., Yessinbekov Z., Thiruvengadam M., et al. Lycopene as a natural antioxidant used to prevent human health disorders. Antioxidants. 2020;9:706. doi: 10.3390/antiox9080706.", "ArticleIdList": ["10.3390/antiox9080706", "PMC7464847", "32759751"]}, {"Citation": "Li Y.-Z., Liang W.-N., Zhang G.-W., Weng Z.-Q., Zhong Y., Xu S., Shang X.-J. Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms. Zhonghua Nan Ke Xue. 2019;25:1001\u20131004.", "ArticleIdList": ["32233234"]}, {"Citation": "Kutwin P., Falkowski P., Lowicki R., Borowiecka-Kutwin M., Konecki T. Are we sentenced to pharmacotherapy? Promising role of lycopene and vitamin A in benign urologic conditions. Nutrients. 2022;14:859. doi: 10.3390/nu14040859.", "ArticleIdList": ["10.3390/nu14040859", "PMC8874554", "35215508"]}, {"Citation": "Carrasco C., Blanco L., Abengozar A., Beatriz-Rodiguez A. Effects of lycopene-enriched, organic, extra virgin olive oil on benign prostatic hyperplasia: A pilot study. Altern. Ther. Health Med. 2022;28:8\u201315.", "ArticleIdList": ["33421040"]}, {"Citation": "Morgia G., Vespasiani G., Pareo R.M., Voce S., Madonia M., Carini M., Ingrassia A., Terrone C., Gentile M., Carrino M., et al. Serenoa repens + selenium + lycopene vs. tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: A phase IV, non-inferiority, open-label, clinical study (SPRITE study) BJU Int. 2018;22:317\u2013325. doi: 10.1111/bju.14209.", "ArticleIdList": ["10.1111/bju.14209", "29569389"]}, {"Citation": "Cormio L., Calo B., Falagario U., Iezzi M., Lamolinara A., Vitaglione P., Silecchia G., Carrieri G., Fogliano V., Iacobelli S., et al. Improvement of urinary tract symptoms and quality of life in benign prostatic hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: A phase II prospective, randomized, double-blinded, placebo-controlled study. J. Transl. Med. 2021;19:24.", "ArticleIdList": ["PMC7789791", "33407599"]}, {"Citation": "Schmeusser B., Levin B., Lama D., Sidana A. Hundred years of transperineal prostate biopsy. Ther. Adv. Urol. 2022;14:1\u201312. doi: 10.1177/17562872221100590.", "ArticleIdList": ["10.1177/17562872221100590", "PMC9128053", "35620643"]}, {"Citation": "Nugroho E.A., Kemara S.A., Supil T. Effect of dutasteride and a tomato-lycopene extract in reducing blood loss after transurethral resection of the prostate. Urol. Sci. 2019;30:216\u2013219. doi: 10.4103/UROS.UROS_152_18.", "ArticleIdList": ["10.4103/UROS.UROS_152_18"]}, {"Citation": "Subba S., Pradhan K. A comprehensive review on the common plants with remarkable medicinal properties: Urtica dioica. J. Med. Plant Stud. 2022;10:87\u201391. doi: 10.22271/plants.2022.v10.i6b.1492.", "ArticleIdList": ["10.22271/plants.2022.v10.i6b.1492"]}, {"Citation": "Taheri Y., Quispe C., Herrera-Bravo J., Sharifit-Rad J., Ezzat S.M., Merghany R.M., Shaheen S., Azmi L., Cho W.C. Urtica dioica-derived phytochemicals for pharmaceutical and therapeutic applications. Evid. -Based Complement. Altern. Med. 2022:4024331. doi: 10.115/2022/4024331.", "ArticleIdList": ["10.115/2022/4024331", "PMC8894011", "35251206"]}, {"Citation": "Singh M., Sengar B. Urtica dioica L. (Stinging Nettle): Morphological, phytochemical, cultivation practices and biological potential: A review. Int. J. Pharamco. Phytochem. Res. 2021;13:1\u20137."}, {"Citation": "Jaiswal V., Lee H.-J. Antioxidant activity of Urtica dioica: An important property contributing to multiple biological activities. Antioxidants. 2022;11:2494. doi: 10.3390/antiox11122494.", "ArticleIdList": ["10.3390/antiox11122494", "PMC9774934", "36552702"]}, {"Citation": "Kumari K., Magar S.K., Thapa R., Lamsal A., Bhandari S., Maharjan R., Shrestha S., Shrestha J. Nutritional and pharmacological importance of stinging nettle (Urtica dioica): A review. Heliyon. 2022;8:e09717.", "ArticleIdList": ["PMC9253158", "35800714"]}, {"Citation": "Devkota H.P., Paudel K.R., Khanal S., Baral A., Panth N., Adhikari-Devkota A., Jha N.K., Das N., Singh S.K., Chellappan D.K., et al. Stinging nettle (Urtica dioica L).: Nutritional composition, bioactive compounds, and food functional properties. Molecules. 2022;27:5219. doi: 10.3390/molecules27165219.", "ArticleIdList": ["10.3390/molecules27165219", "PMC9413031", "36014458"]}, {"Citation": "De Vico G., Guida V., Carella F. Urtica dioica (Stinging Nettle): A neglected plant with emerging growth promoter/immunostimulant properties for farmed fish. Front. Physiol. 2018;9:285. doi: 10.3389/fphys.2018.00285.", "ArticleIdList": ["10.3389/fphys.2018.00285", "PMC5879320", "29632497"]}, {"Citation": "Kregiel D., Pawikowka E., Antolak H. Urtica supp: Ordinary plants with extraordinary properties. Molecules. 2018;23:1664. doi: 10.3390/molecules23071664.", "ArticleIdList": ["10.3390/molecules23071664", "PMC6100552", "29987208"]}, {"Citation": "Mahboubi M. Urtica dioica in the management of benign prostatic hyperplasia (BPH) Nat. Prod. J. 2020;10:535\u2013542."}, {"Citation": "Dhouibi R., Affes H., Salem M.B., Hammami S., Sahnoun Z., Zeghal K.M., Ksouda K. Screening of pharmacological uses of Urtica dioica and other benefits. Prog. Biophys. Mol. Biol. 2020;150:67\u201377. doi: 10.1016/j.pbiomolbio.2019.05.008.", "ArticleIdList": ["10.1016/j.pbiomolbio.2019.05.008", "31163183"]}, {"Citation": "Krajewska A., Mietlinska K. Determining the parameters of the Stinging Nettle (Urtica dioica L.) hydrolate distillation process. Molecules. 2022;27:3912. doi: 10.3390/molecules27123912.", "ArticleIdList": ["10.3390/molecules27123912", "PMC9230648", "35745034"]}, {"Citation": "Gendron F., Nilson S., Ziffle V., Johnny S., Louie D., Diamente P. Anti-microbial effects of selected bacterial species and alkaloid and saponin content of Rosa nutkana C. Prel (Nattka Rose) and Urtica dioica L. (Stinging Nettle) extracts. Am. J. Plant Sci. 2021;12:720\u2013733."}, {"Citation": "Franciskovic M., Gonzalez-Perez R., Orcic D., de Medina F.S., Martinez-Augustin O., Svirecev E., Simin N., Mimica-Dakic N. Chemical composition and immune-modulatory effects of Urtica dioica L. (Stinging Nettle) extracts. Phytother. Res. 2017;31:1183\u20131191. doi: 10.1002/ptr.5836.", "ArticleIdList": ["10.1002/ptr.5836", "28544187"]}, {"Citation": "Grauso L., de Falco B., Lanzotti V., Moti R. Stinging nettle, Urtica dioica L.: Botanical, phytochemical and pharmacology. Overview. Phytochem. Rev. 2020;19:1341\u20131371. doi: 10.1007/s11101-020-09680-x.", "ArticleIdList": ["10.1007/s11101-020-09680-x"]}, {"Citation": "Sararinejad M.R. Urtica dioica for the treatment of benign prostatic hyperplasia: Prospective, randomized, double-blind, placebo-controlled, cross-over study. J. Herb. Pharmacother. 2005;5:1\u201311. doi: 10.1080/J157v05n04_01.", "ArticleIdList": ["10.1080/J157v05n04_01", "16635963"]}, {"Citation": "Karami A.A., Sheikhsoleimani S., Memarzadeh M.R., Haddadi E., Bakhshpour M., Mohammadi N., Mirhashemi S.M. Urtica dioica root extract on clinical and biochemical parameters in patients with benign prostatic hyperplasia, randomized controlled trail. Pak. J. Biol. Sci. 2020;23:1338\u20131344.", "ArticleIdList": ["32981268"]}, {"Citation": "Ibishev K.A., Krainy P.A., Mitusov V.V., Sizyakin D.V., Majomedov G.A. A comparative analysis of the effectiveness of Serenoa repens and Serenoa repens in combination with Urtica dioica for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue. Urologiia. 2019;4:40\u201346. doi: 10.18565/urology.2019.16.40-46.", "ArticleIdList": ["10.18565/urology.2019.16.40-46", "31184016"]}, {"Citation": "Kirschner-Hermans R., Funk P., Leistner N. WS PRO 160/120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH. Ther. Adv. Urol. 2019;11:1\u201312. doi: 10.1177/1756287219879533.", "ArticleIdList": ["10.1177/1756287219879533", "PMC6791037", "31656534"]}, {"Citation": "Saponaro M., Giacomini I., Morandin G., Cocetta V., Ragazzi E., Orso G., Carnevali I., Berretta M., Mancini M., Pagno F., et al. Serenoa repens and Urtica dioica fixed combination: In vitro-validation of a therapy for benign prostatic hyperplasia (BPH) Int. J. Mol. Sci. 2020;21:9178. doi: 10.3390/ijms21239178.", "ArticleIdList": ["10.3390/ijms21239178", "PMC7730996", "33276425"]}, {"Citation": "Heiss M.L., Heiss R.J. The Story of Tea: A Culture History and Drinking Guide. TenSpeed Press; Berkeley, CA, USA: 2007. pp. 4\u201331."}, {"Citation": "Joliffe L. Chapter 6. The Lure of Tea: History, traditions, and attractions. In: Michael C., Sharples L., Cambourne B., editors. Food Tourism Around The World. Butterworth-Heinemann, Elsevier; Burlington, MA, USA: 2003. pp. 121\u2013136."}, {"Citation": "Amin R.A., Dey B.K., Omari N.E., Bouyahya A., Drouet S., Hano C., Sharifi-Rad J. Green Tea and Its Numerous Health Benefits. IntechOpen; Rijeka, Croatia: 2022. pp. 1\u201314.", "ArticleIdList": ["10.5772/intechopen.107368"]}, {"Citation": "Reygaert W. An update on the health benefits of green tea. Beverages. 2017;3:6. doi: 10.3390/beverages3010006.", "ArticleIdList": ["10.3390/beverages3010006"]}, {"Citation": "Mokbel K., Wazir U., Mokbel K. Chemoprevention of prostate cancer by natural agents: Evidence from molecular and epidemiological studies. Anticancer Res. 2019;39:5231\u20135259. doi: 10.21873/anticanres.13720.", "ArticleIdList": ["10.21873/anticanres.13720", "31570421"]}, {"Citation": "Taib W.H., Daoud S., Mahmod A.I., Hamed R.A., Awajan D., Abuarab S.F., Odeh L.H., Khater S., Kury L.T. Plants as a source of anticancer agents: From bench to bedside. Molecules. 2022;27:4818.", "ArticleIdList": ["PMC9369847", "35956766"]}, {"Citation": "Wang X., Ma Y., Xu Q., Shikov A.N., Pozharitskaya O.N., Flisyuk E.V., Liu M., Li H., Vargus-Murga L., Duez P. Flavonoids and saponins: What have we got or missed? Phytomedicine. 2023;109:154580. doi: 10.1016/j.phymed.2022.154580.", "ArticleIdList": ["10.1016/j.phymed.2022.154580", "36610132"]}, {"Citation": "Khan N., Mukhtar H. Tea polyphenols in promotion of human health. Nutrients. 2019;11:39. doi: 10.3390/nu11010039.", "ArticleIdList": ["10.3390/nu11010039", "PMC6356332", "30585192"]}, {"Citation": "Fernandez V.A., Toledano L.A., Lozano N.P., Tapia E.N., Roig M.D.G., De la Torre Fornell R., Algar O.G. Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers. Antioxidants. 2020;9:440. doi: 10.3390/antiox9050440.", "ArticleIdList": ["10.3390/antiox9050440", "PMC7278615", "32438698"]}, {"Citation": "Hayat K., Iqbal H., Malik U., Bilal U., Mushtaq S. Tea and its consumption: Benefits and risks. Crit. Rev. Food Sci. Nutr. 2015;7:939\u2013954. doi: 10.1080/10408398.2012.678949.", "ArticleIdList": ["10.1080/10408398.2012.678949", "24915350"]}, {"Citation": "Khan A., Chauhan K., Ross H., Parra N.S., Magagna J., Wang M., Zhu P., Erwin R., Halegoua-DeMarzio D. A comprehensive review on the use of herbal dietary supplements in the USA, reasons for their use, and review of potential hepatotoxicity. Livers. 2022;2:119\u2013138. doi: 10.3390/livers2030011.", "ArticleIdList": ["10.3390/livers2030011"]}, {"Citation": "Johnson J.J., Bailey H.H., Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. PhytoMedicine. 2010;17:3\u201313. doi: 10.1016/j.phymed.2009.09.011.", "ArticleIdList": ["10.1016/j.phymed.2009.09.011", "PMC2789276", "19959000"]}, {"Citation": "Zhou J., Lei Y., Chen J., Zhou X. Potential ameliorative effects of epigallocatechin-3-gallate against testostosterone-induced benign prostatic hyperplasia and fibrosis in rats. Int. Immunopharmacol. 2018;64:162\u2013169. doi: 10.1016/j.intimp.2018.08.038.", "ArticleIdList": ["10.1016/j.intimp.2018.08.038", "30179845"]}, {"Citation": "Sharifi-Zahabi E., Hajizadeh-Sharafabad F., Abdollahzad H., Afsaneh D., Shidfar F. The effect of green tea on prostate specific antigen (PSA): A systematic review and meta-analysis of randomized controlled trials. Comp. Ther. Med. 2021;57:102659. doi: 10.1016/j.ctim.2020.102659.", "ArticleIdList": ["10.1016/j.ctim.2020.102659", "33400976"]}, {"Citation": "Na H.-K., Surh Y.-J. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem. Toxicol. 2008;46:1271\u20131278. doi: 10.1016/j.fct.2007.10.006.", "ArticleIdList": ["10.1016/j.fct.2007.10.006", "18082923"]}, {"Citation": "Yao H.-T., Li C.-C., Chang C.-H. Epigallocatechin-3-gallate reduced hepatic oxidative stress and lowers CYP-mediated bioactivation and toxicity of acetaminophen in rats. Nutrients. 2019;11:1862. doi: 10.3390/nu11081862.", "ArticleIdList": ["10.3390/nu11081862", "PMC6723635", "31405142"]}, {"Citation": "Zhang Y., Liu C., Huang J., Liu Z. A review of physiological activities fo EGCG and the role in improving fertility in humans/mammals. Biomed. Pharmacother. 2020;127:110186. doi: 10.1016/j.biopha.2020.110186.", "ArticleIdList": ["10.1016/j.biopha.2020.110186", "32559843"]}, {"Citation": "Rago V., Di Agostino S. Novel insight into the role of the antioxidants in prostate pathology. Antioxidants. 2023;12:289. doi: 10.3390/antiox12020289.", "ArticleIdList": ["10.3390/antiox12020289", "PMC9951863", "36829848"]}, {"Citation": "Beyaz S., Gok O., Aslan A. The therapeutic effects and antioxidant properties of epigallocatechin-3-gallate: A new review. Int. J. Second. Metab. 2022;9:125\u2013136. doi: 10.21448/ijsm.1017559.", "ArticleIdList": ["10.21448/ijsm.1017559"]}, {"Citation": "Steinmann J., Buer J., Pietschmann T., Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharm. 2012;16:1059\u20131073. doi: 10.1111/bph.12009.", "ArticleIdList": ["10.1111/bph.12009", "PMC3594666", "23072320"]}, {"Citation": "Reygaert W.C. Green tea catechins: Their use in treating and preventing infectious diseases. BioMed Res. Int. 2018:9105261. doi: 10.1155/2018/9105261.", "ArticleIdList": ["10.1155/2018/9105261", "PMC6076941", "30105263"]}, {"Citation": "Sun J., Dong S., Li J., Zhao H. A comprehensive review on the effects of green tea and its components on the immune function. Food Sci. Human Wellness. 2022;11:1143\u20131155. doi: 10.1016/j.fshw.2022.04.008.", "ArticleIdList": ["10.1016/j.fshw.2022.04.008"]}, {"Citation": "Miyata Y., Shida Y., Hakariya T., Sakai H. Anti-cancer effects of green tea polyphenols against prostate cancer. Molecules. 2019;24:193. doi: 10.3390/molecules24010193.", "ArticleIdList": ["10.3390/molecules24010193", "PMC6337309", "30621039"]}, {"Citation": "Musial C., Kuban-Jankowska A., Gorska-Ponikowska M. Beneficial properties of green tea catechins. Int. J. Mol. Sci. 2020;21:1744. doi: 10.3390/ijms21051744.", "ArticleIdList": ["10.3390/ijms21051744", "PMC7084675", "32143309"]}, {"Citation": "Katz A., Efos M., Kaminetsky J., Herrlinger K., Chirouzes D., Ceddia M. A green and black tea extract benefits urological health in men with lower urinary tract symptoms. Ther. Adv. Urol. 2014;6:89\u201396. doi: 10.1177/1756287214526924.", "ArticleIdList": ["10.1177/1756287214526924", "PMC4003843", "24883106"]}, {"Citation": "Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS), U.S. National Library of Medicine, Clinical Trials.gov.  [(accessed on 5 January 2023)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04300855."}, {"Citation": "Cardona F., Andres-Lacueva C., Tulopani S., Tinahones F.J., Queipo-Ortufio M.I. Benefits of polyphenols on gut microbiota and implications in human health. J. Nutr. Biochem. 2013;24:1415\u20131422. doi: 10.1016/j.jnutbio.2013.05.001.", "ArticleIdList": ["10.1016/j.jnutbio.2013.05.001", "23849454"]}, {"Citation": "Rodriguez-Daza M.C., Pulido-Mateos E.C., Lupien-Melileur J., Guyonnet D., Desjardins Y., Roy D. Polyphenol-mediated gut microbiota modulation: Toward prebiotics and further. Front. Nutr. 2021;8:689456. doi: 10.3389/fnut.2021.689456.", "ArticleIdList": ["10.3389/fnut.2021.689456", "PMC8276758", "34268328"]}, {"Citation": "Garcia-Vallalba R., Gimenez-Batida J.A., Cortes-Martin A., Avila-Galvez M.A., Tomas-Bareran F.A., Selma M.V., Espin J.C., Gonzalez-Sarrias A. Urolithins: A comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol. Nutr. Food Res. 2022;66:20101019. doi: 10.1002/mnfr.202101019.", "ArticleIdList": ["10.1002/mnfr.202101019", "PMC9787965", "35118817"]}, {"Citation": "Sanchez-Gonzalez C., Ciudad C.J., Noe V., Izquierdo-Pulido M. Walnut polyphenol metabolites, urolithins A and B, inhibit expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells. Food Funct. 2014;5:2922\u20132930. doi: 10.1039/C4FO00542B.", "ArticleIdList": ["10.1039/C4FO00542B", "25214070"]}, {"Citation": "Liu C., Boeren S., Estruch I.M., Rietjens I.M.C.M. The gut microbial metabolite pyrogallol is a more potent inducer of Nrf2-associated gene expression than its parent compound green tea (-)-epigallocatechin gallate. Nutrients. 2022;14:3392. doi: 10.3390/nu14163392.", "ArticleIdList": ["10.3390/nu14163392", "PMC9414524", "36014899"]}, {"Citation": "Al-Harbi S.A., Abdulrahman A.O., Zamzami M., Khan M.I. Urolithins: The gut base polyphenol metabolites of ellagitannins in cancer prevention, a review. Front. Nutr. 2021;8:647582. doi: 10.3389/fnut.2021.647582.", "ArticleIdList": ["10.3389/fnut.2021.647582", "PMC8215145", "34164422"]}, {"Citation": "Mokhtari R.B., Homayouni T.S., Baluch N., Morgatskaya E., Kumar S., Das B., Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201338043. doi: 10.18632/oncotarget.16723.", "ArticleIdList": ["10.18632/oncotarget.16723", "PMC5514969", "28410237"]}, {"Citation": "Ayoub N.A. Novel combination therapies for treatment of solid cancers. Front. Oncol. 2021;11:708943. doi: 10.3389/fonc.2021.708943.", "ArticleIdList": ["10.3389/fonc.2021.708943", "PMC8250861", "34222030"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "2", "Day": "23"}, {"Year": "2023", "Month": "3", "Day": "8"}, {"Year": "2023", "Month": "3", "Day": "9"}, {"Year": "2023", "Month": "3", "Day": "30", "Hour": "6", "Minute": "11"}, {"Year": "2023", "Month": "3", "Day": "29", "Hour": "1", "Minute": "37"}, {"Year": "2023", "Month": "3", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "13"}], "PublicationStatus": "epublish", "ArticleIdList": ["36982560", "PMC10058027", "10.3390/ijms24065486", "ijms24065486"]}}], "PubmedBookArticle": []}